The ‘best’ vaccine: how does Pfizer fare against the others?


The ‘best’ vaccine: how does Pfizer fare against the others?

The brand approved for emergency use in SA wins for efficacy but loses for its dosing regimen

Senior science reporter

The Pfizer-BioNTech vaccine, approved for emergency use this week by the SA Health Products Regulatory Authority, has some advantages over other Covid-19 vaccines already here or due to arrive. But it’s not a clear winner in all categories and comes last in some.

According to a new study, carried out by Novateur Ventures, a Canadian Covid-19 resource centre, and led by Queen’s University, the Pfizer-BioNtech vaccine tops the charts alongside Moderna when it comes to efficacy.

The researchers carried out a comparative analysis of 12 vaccines that had already initiated or announced their phase three clinical trials by early November last year...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email or call 0860 52 52 00.

Previous Article